CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brach, M. A.
Right arrow Articles by Herrmann, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brach, M. A.
Right arrow Articles by Herrmann, F.

Cell Growth & Differentiation, Vol 3, Issue 7 421-427, Copyright © 1992 by American Association of Cancer Research


ARTICLES

Activation of NF-kappa B by interleukin 2 in human blood monocytes

MA Brach, HJ Gruss, D Riedel, R Mertelsmann and F Herrmann
Department of Hematology, University of Freiburg Medical Center, Germany.

We report here that interleukin 2 (IL-2) acts on human blood monocytes by enhancing binding activity of the transcription factor NF-kappa B to its consensus sequence in the 5' regulatory enhancer region of the IL-2 receptor alpha chain (p55). Similarly, IL-2 activates NF-kappa B in the human monocytic cell line U 937, but not in resting human T-cells. This effect is detectable within 15 min and peaks 1 h after exposure to IL-2. Enhanced NF-kappa B binding activity is followed by functional activation in that inducibility of the IL-2 receptor alpha chain is mediated by enhanced NF-kappa B binding and that a heterologous promoter containing the NF-kappa B consensus sequence (-291 to -245) of the IL-2 receptor alpha chain gene is activated. In addition, IL-2 is capable of increasing transcript levels of the p50 gene coding for the p50 subunit of the NF-kappa B transcription factor, whereas mRNA levels of the p65 NF-kappa B gene remained unchanged.


This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Schuster, C. Plaza-Sirvent, A.-M. Matthies, U. Heise, A. Jeron, D. Bruder, A. Visekruna, J. Huehn, and I. Schmitz
c-REL and I{kappa}BNS Govern Common and Independent Steps of Regulatory T Cell Development from Novel CD122-Expressing Pre-Precursors
J. Immunol., August 1, 2017; 199(3): 920 - 930.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Zhou, J. Zhang, M. G. Lichtenheld, and G. G. Meadows
A Role for NF-{kappa}B Activation in Perforin Expression of NK Cells Upon IL-2 Receptor Signaling
J. Immunol., August 1, 2002; 169(3): 1319 - 1325.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M.-Y. Zhang, S.-C. Sun, L. Bell, and B. A. Miller
NF-kappa B Transcription Factors Are Involved in Normal Erythropoiesis
Blood, June 1, 1998; 91(11): 4136 - 4144.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. R. Boothby, A. L. Mora, D. C. Scherer, J. A. Brockman, and D. W. Ballard
Perturbation of the T Lymphocyte Lineage In Transgenic Mice Expressing a Constitutive Repressor of Nuclear Factor (NF)-{kappa}B
J. Exp. Med., June 2, 1997; 185(11): 1897 - 1907.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1992 by the American Association of Cancer Research.